A Phase 3 interventional study of Estradiol acetate and Estradiol in Hormone Replacement Therapy, sponsored by Warner Chilcott. Completed at 32 sites in United States. Open to female participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2013-04-22.
Sponsored by Warner Chilcott (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Multicenter, double-blind, controlled, parallel group, randomized study to compare the clinical benefit of Estradiol acetate tablets, estradiol tablets and conjugated equine estrogen tablets, each administered orally, once daily, to postmenopausal women.
Warner Chilcott is the lead sponsor of 58 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
First submitted before Warner Chilcott became part of AbbVie.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Non-hysterectomized women:
Hysterectomized women:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Estradiol acetate
Drug: Estradiol
Drug: Conjugated equine estrogens
Tablet containing 0.9 mg E3A, daily oral administration.
Tablet containing 1 mg estradiol, daily oral administration.
Also known as: Estrace
Tablet containing 0.625 mg CEE, daily oral administration.
Also known as: Premarin
Mean Change From Baseline in the Number of Moderate to Severe Hot Flushes, Week 4, ITT (Intention to Treat) Population
Severity of hot flush definitions: mild - sensation of heat without perspiration, moderate - sensation of heat with perspiration, able to continue activity, severe - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep
Time frame: Baseline to Week 4
Mean Change From Baseline in the Number of Moderate to Severe Hot Flushes, Week 12, ITT Population
Severity of hot flush definitions: mild - sensation of heat without perspiration, moderate - sensation of heat with perspiration, able to continue activity, severe - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep
Time frame: Baseline to Week 12
Mean Change From Baseline in the Severity of Moderate to Severe Hot Flushes, Week 4, ITT Population
Patient self-reported outcome. Severity of hot flush definitions: mild (1) - sensation of heat without perspiration, moderate (2) - sensation of heat with perspiration, able to continue activity, severe (3) - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep. Minimum 0/no hot flushes, Maximum 3/all severe hot flushes. Lower the score the greater the improvement in reducing hot flushes.
Time frame: Baseline to Week 4
Mean Change From Baseline in the Severity of Moderate to Severe Hot Flushes, Week 12, ITT Population
Patient self-reported outcome. Severity of hot flush definitions: mild (1) - sensation of heat without perspiration, moderate (2) - sensation of heat with perspiration, able to continue activity, severe (3) - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep. Minimum 0/no hot flushes, Maximum 3/all severe hot flushes. Lower the score the greater the improvement in reducing hot flushes.
Time frame: Baseline to Week 12
Mean Change From Baseline in Total Urogenital Symptom Score, Week 4, ITT Population
Urogenital Symptom Severity scored none=0, mild=1, moderate=2, severe=3.
Time frame: Baseline to Week 4
Change From Baseline in Total Urogenital Symptom Score, Week 8, ITT Population
Urogenital Symptom Severity scored none=0, mild=1, moderate=2, severe=3.
Time frame: Baseline to Week 8
Change From Baseline in Total Urogenital Symptom Score, Week 12, ITT Population
Urogenital Symptom Severity scored none=0, mild=1, moderate=2, severe=3.
Time frame: Baseline to Week 12
Enrollment of postmenopausal women for relief of hot flushes and urogenital symptoms beginning Feb '03 at 33 sites in the US.
| Milestone | Estradiol Acetate (E3A) | Estradiol | Conjugated Equine Estrogens (CEE) |
|---|---|---|---|
| Started | 79 | 85 | 85 |
| Completed | 68 | 73 | 72 |
| Not completed | 11 | 12 | 13 |
| Withdrew: Adverse event | 2 | 3 | 3 |
| Withdrew: Lost to follow-up | 2 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 2 | 6 |
| Withdrew: Surgery, moving, personal, abn. labs | 4 | 4 | 2 |
| Withdrew: Withdrawal by subject | 3 | 1 | 1 |
| Withdrew: No study drug taken | 0 | 1 | 0 |
Severity of hot flush definitions: mild - sensation of heat without perspiration, moderate - sensation of heat with perspiration, able to continue activity, severe - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep
| Change in Hot Flush Count | Estradiol Acetate (E3A) | Estradiol | Conjugated Equine Estrogens (CEE) |
|---|---|---|---|
| Mean Change From Baseline in the Number of Moderate to Severe Hot Flushes, Week 4, ITT (Intention to Treat) Population | -54.1 ± 4.5 | -62.0 ± 4.5 | -54.5 ± 4.3 |
Patient self-reported outcome. Severity of hot flush definitions: mild (1) - sensation of heat without perspiration, moderate (2) - sensation of heat with perspiration, able to continue activity, severe (3) - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep. Minimum 0/no hot flushes, Maximum 3/all severe hot flushes. Lower the score the greater the improvement in reducing hot flushes.
| Change in Score | Estradiol Acetate (E3A) | Estradiol | Conjugated Equine Estrogens (CEE) |
|---|---|---|---|
| Mean Change From Baseline in the Severity of Moderate to Severe Hot Flushes, Week 4, ITT Population | -0.53 ± 0.106 | -0.51 ± 0.106 | -0.59 ± 0.102 |
Severity of hot flush definitions: mild - sensation of heat without perspiration, moderate - sensation of heat with perspiration, able to continue activity, severe - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep
| Change in Hot Flush Count | Estradiol Acetate (E3A) | Estradiol | Conjugated Equine Estrogens (CEE) |
|---|---|---|---|
| Mean Change From Baseline in the Number of Moderate to Severe Hot Flushes, Week 12, ITT Population | -63.6 ± 4.8 | -72.2 ± 4.7 | -67.2 ± 4.6 |
Patient self-reported outcome. Severity of hot flush definitions: mild (1) - sensation of heat without perspiration, moderate (2) - sensation of heat with perspiration, able to continue activity, severe (3) - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep. Minimum 0/no hot flushes, Maximum 3/all severe hot flushes. Lower the score the greater the improvement in reducing hot flushes.
| Change in Score | Estradiol Acetate (E3A) | Estradiol | Conjugated Equine Estrogens (CEE) |
|---|---|---|---|
| Mean Change From Baseline in the Severity of Moderate to Severe Hot Flushes, Week 12, ITT Population | -1.05 ± 0.127 | -1.34 ± 0.125 | -1.17 ± 0.122 |
Urogenital Symptom Severity scored none=0, mild=1, moderate=2, severe=3.
| Change in Score | Estradiol Acetate (E3A) | Estradiol | Conjugated Equine Estrogens (CEE) |
|---|---|---|---|
| Mean Change From Baseline in Total Urogenital Symptom Score, Week 4, ITT Population | -1.89 ± 0.413 | -2.26 ± 0.407 | -1.96 ± 0.398 |
Urogenital Symptom Severity scored none=0, mild=1, moderate=2, severe=3.
| Change in Score | Estradiol Acetate (E3A) | Estradiol | Conjugated Equine Estrogens (CEE) |
|---|---|---|---|
| Change From Baseline in Total Urogenital Symptom Score, Week 8, ITT Population | -1.96 ± 0.432 | -2.58 ± 0.425 | -2.42 ± 0.416 |
Urogenital Symptom Severity scored none=0, mild=1, moderate=2, severe=3.
| Change in Score | Estradiol Acetate (E3A) | Estradiol | Conjugated Equine Estrogens (CEE) |
|---|---|---|---|
| Change From Baseline in Total Urogenital Symptom Score, Week 12, ITT Population | -2.49 ± 0.437 | -2.59 ± 0.431 | -2.52 ± 0.422 |
Collected over 7 months. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Estradiol Acetate (E3A) | — | 0/79 (0%) | 19/79 (24.1%) |
| Estradiol | — | 1/84 (1.2%) | 25/84 (29.8%) |
| Conjugated Equine Estrogens (CEE) | — | 0/85 (0%) | 30/85 (35.3%) |
| Event | Estradiol Acetate (E3A) | Estradiol | Conjugated Equine Estrogens (CEE) |
|---|---|---|---|
| metrorrhagiaReproductive system and breast disorders | 0/79 | 1/84 | 0/85 |
| Event | Estradiol Acetate (E3A) | Estradiol | Conjugated Equine Estrogens (CEE) |
|---|---|---|---|
| HeadacheNervous system disorders | 3/79 | 5/84 | 6/85 |
| Breast TendernessReproductive system and breast disorders | 2/79 | 5/84 | 5/85 |
| NauseaGastrointestinal disorders | 4/79 | 1/84 | 2/85 |
| Abdominal DistentionGastrointestinal disorders | 1/79 | 4/84 | 2/85 |
| MetrorrhagiaReproductive system and breast disorders | 2/79 | 3/84 | 4/85 |
| AnxietyPsychiatric disorders | 3/79 | 0/84 | 2/85 |
| NasopharyngitisNervous system disorders | 1/79 | 3/84 | 0/85 |
| Vaginosis FungalInfections and infestations | 0/79 | 1/84 | 3/85 |
| Weight IncreasedInvestigations | 1/79 | 1/84 | 3/85 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/79 | 2/84 | 3/85 |
| Age Continuous(years) | Estradiol Acetate (E3A) | Estradiol | Conjugated Equine Estrogens (CEE) | Total |
|---|---|---|---|---|
| Mean | 52.2 ± 6.6 | 52.3 ± 7.0 | 53.8 ± 6.3 | 52.8 ± 6.7 |
| Sex: Female, Male(Participants) | Estradiol Acetate (E3A) | Estradiol | Conjugated Equine Estrogens (CEE) | Total |
|---|---|---|---|---|
| Female | 79 | 85 | 85 | 249 |
| Male | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Estradiol Acetate (E3A) | Estradiol | Conjugated Equine Estrogens (CEE) | Total |
|---|---|---|---|---|
| United States | 79 | 85 | 85 | 249 |
The record gives a start of Feb 2003, a primary completion of Sep 2003 and a completion of Sep 2003. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2011, 7 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Estradiol